Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 15;39(9):1125-1132.
doi: 10.1097/QAD.0000000000004171. Epub 2025 Mar 6.

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption

Graeme Moyle  1 , Joshua Gruber  2 , Megan Dunbar  2 , Janna Radtchenko  3 , Andrew J Frick  3 , Andrea Marongiu  2 , Paul E Sax  4 , Travis Lim  2 , Steven Santiago  5 , Paul Benson  6 , Charles Walworth  7 , Richard A Elion  3
Affiliations

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption

Graeme Moyle et al. AIDS. .

Abstract

Objective: Treatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be potentially started or restarted after antiretroviral treatment interruption.

Methods: Data from the TRIO US HIV cohort were used to identify adult people with HIV initiating a new ART regimen from January 2021 to November 2023 and describe prevalence of treatment interruptions (defined as ≥90 days without dispensed ART). Virologic outcomes were assessed among those restarting or switching to B/F/TAF after treatment interruption.

Results: Of 2710 people with HIV, 765 (28%) experienced treatment interruption. Compared to individuals without treatment interruptions, those with treatment interruptions had higher proportion of women (24 vs. 19%), Black race (50 vs. 35%), substance use (14 vs. 9%), CD4 + cell count less than 200 cells/mm 3 (15 vs. 8%) and lower proportion with commercial insurance (48 vs. 62%) or virologic suppression at initiation (76 vs. 85%). Among 379 who restarted or switched to B/F/TAF following treatment interruption, 245 (65%) were suppressed at restart; 137 (56%) had at least one viral load after treatment interruption, of whom 129 (94%) maintained suppression. Of 87 with unknown viral status at restart, 46 (53%) had at least one viral load during follow-up, of whom 44 (96%) achieved suppression. Among 47 viremic at restart, 27 (57%) had at least one viral load after treatment interruption. Of them, 70% were suppressed during follow-up. No integrase inhibitor resistance emergence was observed.

Conclusion: High levels of suppression following treatment interruption may suggest B/F/TAF regimen forgiveness making it an appropriate choice for treatment switch or restart.

Keywords: adherence; antiretroviral resistance; antiretroviral therapy; bictegravir; therapy restart; treatment interruptions; viral suppression.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study population selection.
Fig. 2
Fig. 2
Virologic status at restart on B/F/TAF (n = 379).
Fig. 3
Fig. 3
Viral suppression after restart on B/F/TAF.
Fig. 4
Fig. 4
Genotypic testing any time prior to treatment interruption in people with HIV who restarted/switched to B/F/TAF after TI.
See this image and copyright information in PMC

References

    1. What's new: adult and adolescent ARV HIV Clinical Guidelines | NIH. September 12, 2024. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult.... [Accessed 5 December 2024].
    1. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46:292–307. - PMC - PubMed
    1. Shuter J. Forgiveness of nonadherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:769–773. - PubMed
    1. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence 2019; 13:475–490. - PMC - PubMed
    1. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open 2013; 3:e003028. - PMC - PubMed

MeSH terms